Six-month interim report (Q2) 2025 (unaudited)

About this update from Alk-abello A/s Class B

ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe were ahead of plan, supporting 12% overall revenue growth, despite phasing of product shipments to International markets. The operating profit (EBIT) increased by 41%, and the full-year revenue outlook has been upgraded. Q2 performance highlights Comparative figures for Q2 2024 are shown in brackets. G rowth rates are stated in local currencies (l.c.), unless otherwise indicated. Financial highlights Allergy+ strategy highlights 2025 full-year outlook On 12 August 2025, ALK upgraded the full-year outlook based on the better-than-expected performance in Q2 and an improved outlook for the remainder of the year: Commenting on the Q2 results, CEO Peter Halling said: “Q2 marked a step change in the execution of key strategic growth initiatives, notably the rollout of our respiratory tablets for young children, the launch of the neffy ® adrenaline spray, and the deployment of a dedicated paediatric sales force in the US. While these efforts are still at an early stage, they have started contributing to growth, and we expect their impact to increase from the second half-year onwards. This reinforces our confidence in our ability to deliver sustained, profitable growth by reaching more patients with evidence-based allergy and anaphylaxis solutions." Hørsholm, 21 August 2025 ALK-Abelló A/S For further information, contact: Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 ALK is hosting a conference call for analysts and investors at 1.30 p.m. (CEST) on 21 August 2025 at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net where the relevant presentation will be available shortly before the call begins. To register for the conference call, please use this link and follow the registration instructions. You will receive an email from [email protected] with dial-in details, including a passcode and a pin code. Please make sure to whitelist [email protected] and/or check your spam filter. We advise you to register well in advance and to call in before 1.25 p.m. (CEST). Attachment

View stock analysis, news, and events for Alk-abello A/s Class B